Should minor stroke patients be thrombolyzed? A focused review and future directions

International Journal of Stroke

Volumn 10, Issue 3, 2015, Pages 292-297

  Yu, Amy Y X ^a   Hill, Michael D ^a,b,c   Coutts, Shelagh B ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acute stroke therapy; CT scan; Ischemic stroke; Minor stroke; TIA; tPA

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; HEPARINOID; TICAGRELOR;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DECISION MAKING; DISABILITY; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; MEDICAL HISTORY; NEUROIMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE PATIENT; PROCEDURES; STROKE;

HUMANS; STROKE; THROMBOLYTIC THERAPY;

EID: 84924904670     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12426     Document Type: Review

References (47)

1. Smith EE, Fonarow GC, Reeves MJ etal. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011; 42:3110-3115.
2. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005; 36:2497-2499.
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
4. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
5. Coutts SB, Modi J, Patel SK etal. What causes disability after transient ischemic attack and minor stroke? Results from the CT and MRI in the triage of TIA and minor Cerebrovascular Events to Identify High Risk Patients (CATCH) Study. Stroke 2012; 43:3018-3022.
6. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56:1015-1020.
7. Park TH, Hong KS, Choi JC etal. Validation of minor stroke definitions for thrombolysis decision making. J Stroke Cerebrovasc Dis 2013; 22:482-490.
8. Fischer U, Baumgartner A, Arnold M etal. What is a minor stroke? Stroke 2010; 41:661-666.
9. Strbian D, Piironen K, Meretoja A etal. Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int J Stroke 2013; 8:293-299.
10. Poisson SN, Nguyen-Huynh MN, Johnston SC, Furie KL, Lev MH, Smith WS. Intracranial large vessel occlusion as a predictor of decline in functional status after transient ischemic attack. Stroke 2011; 42:44-47.
11. Wendt M, Tutuncu S, Fiebach JB, Scheitz JF, Audebert HJ, Nolte CH. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores. J Stroke Cerebrovasc Dis 2013; 22:550-553.
12. Martin-Schild S, Albright KC, Tanksley J etal. Zero on the NIHSS does not equal the absence of stroke. Ann Emerg Med 2011; 57:42-45.
13. Yoo AJ, Romero J, Hakimelahi R etal. Predictors of functional outcome vary by the hemisphere of involvement in major ischemic stroke treated with intra-arterial therapy: a retrospective cohort study. BMC Neurol 2010; 10:25.
14. Coutts SB, Hill MD, Campos CR etal. Recurrent events in transient ischemic attack and minor stroke: what events are happening and to which patients? Stroke 2008; 39:2461-2466.
15. Koga H, Takashima Y, Murakawa R, Uchino A, Yuzuriha T, Yao H. Cognitive consequences of multiple lacunes and leukoaraiosis as vascular cognitive impairment in community-dwelling elderly individuals. J Stroke Cerebrovasc Dis 2009; 18:32-37.
16. Sivakumar L, Kate M, Jeerakathil T, Camicioli R, Buck B, Butcher K. Serial montreal cognitive assessments demonstrate reversible cognitive impairment in patients with acute transient ischemic attack and minor stroke. Stroke 2014; 45:1709-1715.
17. Nedeltchev K, Schwegler B, Haefeli T etal. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007; 38:2531-2535.
18. Horton M, Modi J, Patel SK etal. Refinement of imaging predictors of recurrent events following transient ischemic attack and minor stroke. PLoS ONE 2013; 8:e65752.
19. Paul NL, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012; 79:1356-1362.
20. Sato S, Uehara T, Ohara T etal. Factors associated with unfavorable outcome in minor ischemic stroke. Neurology 2014; 83:174-181.
21. Bal S, Menon BK, Demchuk AM, Hill MD. Routine CT angiography in acute stroke does not delay thrombolytic therapy. Can J Neurol Sci 2012; 39:499-501.
22. Krol AL, Dzialowski I, Roy J etal. Incidence of radiocontrast nephropathy in patients undergoing acute stroke computed tomography angiography. Stroke 2007; 38:2364-2366.
23. Kim JT, Park MS, Chang J, Lee JS, Choi KH, Cho KH. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS ONE 2013; 8:e70996.
24. Dubuc V, Singh D, Modi J, Goyal M, Hill MD, Coutts SB. TIA and minor stroke patients with intracranial occlusions in both proximal and distal vessels are most at risk for symptom progression. Cerebrovasc Dis 2014; 38:389-390.
25. Kennedy J, Hill MD, Ryckborst KJ etal. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-969.
26. Wang Y, Wang Y, Zhao X etal. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369:11-19.
27. Simoons ML, Maggioni AP, Knatterud G etal. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342:1523-1528.
28. Zinkstok SM, Engelter ST, Gensicke H etal. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke 2013; 44:1080-1084.
29. Emberson J, Lees KR, Lyden P etal. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; http://dx.doi.org/10.1016/S0140-6736(14)60584-5. [Epub 5 Aug 2014].
30. Huisa BN, Raman R, Neil W, Ernstrom K, Hemmen TM. Intravenous tissue plasminogen activator for patients with minor ischemic stroke. J Stroke Cerebrovasc Dis 2012; 21:732-736.
31. Hassan AE, Zacharatos H, Hassanzadeh B etal. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator? J Stroke Cerebrovasc Dis 2010; 19:116-120.
32. Steffenhagen N, Hill MD, Poppe AY, Buchan AM, Coutts SB. Should you thrombolyse all or any stroke patients with baseline National Institutes of Health stroke scale scores
33. IST-3 Collaborative Group, Sandercock P, Wardlaw JM etal. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.
34. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
35. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245-1251.
36. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31:811-816.
37. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019-2026.
38. Davis SM, Donnan GA, Parsons MW etal. Effects of alteplase beyond 3h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309.
39. Kruetzelmann A, Siemonsen S, Gerloff C etal. Thrombolysis targeting MRI defined tissue at risk in minor stroke. J Neurol Neurosurg Psychiatry 2009; 80:1156-1158.
40. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005; 46:243-252.
41. Greisenegger S, Seyfang L, Kiechl S, Lang W, Ferrari J, Austrian Stroke Unit Registry Collaborators. Thrombolysis in patients with mild stroke: results from the Austrian Stroke Unit Registry. Stroke 2014; 45:765-769.
42. Mishra NK, Lyden P, Grotta JC, Lees KR, VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41:2612-2617.
43. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41:1229-1245.
44. Binbrek AS, Rao NS, Neimane D, Hatou E, Abdulali S, Sobel BE. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. Am J Cardiol 2004; 93:1465-1468.
45. Benedict CR, Refino CJ, Keyt BA etal. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92:3032-3040.
46. Parsons M, Spratt N, Bivard A etal. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366:1099-1107.
47. Armstrong PW, Gershlick AH, Goldstein P etal. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368:1379-1387.